Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
1. 40-o-(2-ethoxyethyl)rapamycin
2. 42-o-(2-ethoxyethyl) Rapamycin
3. Biolimus A9
4. Rapamycin, 42-o-(2-ethoxyethyl)-
5. Trm-986
1. Biolimus A9
2. Trm 986
3. Trm-986
4. 42-o-(2-ethoxyethyl) Rapamycin
5. 40-o-(2-ethoxyethyl)rapamycin
6. 851536-75-9
7. Rapamycin, 42-o-(2-ethoxyethyl)-
8. U36pgf65jh
9. Biolimus-a9
10. A9
11. Umirolimus [inn]
12. Umirolimus [usan:inn]
13. Umirolimus [usan]
14. Unii-u36pgf65jh
15. Umirolimus [who-dd]
16. Ba-9
17. Trm986
18. Chembl2107380
19. Schembl17117902
20. Ex-a3593
21. Zinc169677041
22. Db15527
23. Hy-122402
24. Cs-0085037
25. Q7881588
26. A-9
Molecular Weight | 986.3 g/mol |
---|---|
Molecular Formula | C55H87NO14 |
XLogP3 | 6.8 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 11 |
Exact Mass | 985.61265645 g/mol |
Monoisotopic Mass | 985.61265645 g/mol |
Topological Polar Surface Area | 194 Ų |
Heavy Atom Count | 70 |
Formal Charge | 0 |
Complexity | 1840 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 4 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Anti-Inflammatory Agents
Substances that reduce or suppress INFLAMMATION. (See all compounds classified as Anti-Inflammatory Agents.)
Immunosuppressive Agents
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. (See all compounds classified as Immunosuppressive Agents.)
ABOUT THIS PAGE
52
PharmaCompass offers a list of Umirolimus API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Umirolimus manufacturer or Umirolimus supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Umirolimus manufacturer or Umirolimus supplier.
PharmaCompass also assists you with knowing the Umirolimus API Price utilized in the formulation of products. Umirolimus API Price is not always fixed or binding as the Umirolimus Price is obtained through a variety of data sources. The Umirolimus Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Umirolimus manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Umirolimus, including repackagers and relabelers. The FDA regulates Umirolimus manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Umirolimus API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Umirolimus supplier is an individual or a company that provides Umirolimus active pharmaceutical ingredient (API) or Umirolimus finished formulations upon request. The Umirolimus suppliers may include Umirolimus API manufacturers, exporters, distributors and traders.
click here to find a list of Umirolimus suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Umirolimus DMF (Drug Master File) is a document detailing the whole manufacturing process of Umirolimus active pharmaceutical ingredient (API) in detail. Different forms of Umirolimus DMFs exist exist since differing nations have different regulations, such as Umirolimus USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Umirolimus DMF submitted to regulatory agencies in the US is known as a USDMF. Umirolimus USDMF includes data on Umirolimus's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Umirolimus USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Umirolimus suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Umirolimus as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Umirolimus API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Umirolimus as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Umirolimus and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Umirolimus NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Umirolimus suppliers with NDC on PharmaCompass.
Umirolimus Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Umirolimus GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Umirolimus GMP manufacturer or Umirolimus GMP API supplier for your needs.
A Umirolimus CoA (Certificate of Analysis) is a formal document that attests to Umirolimus's compliance with Umirolimus specifications and serves as a tool for batch-level quality control.
Umirolimus CoA mostly includes findings from lab analyses of a specific batch. For each Umirolimus CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Umirolimus may be tested according to a variety of international standards, such as European Pharmacopoeia (Umirolimus EP), Umirolimus JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Umirolimus USP).